222 related articles for article (PubMed ID: 32529312)
1. Repurposing the Dihydropyridine Calcium Channel Inhibitor Nicardipine as a Na
Ekins S; Puhl AC; Davidow A
Pharm Res; 2020 Jun; 37(7):127. PubMed ID: 32529312
[TBL] [Abstract][Full Text] [Related]
2. Repurposing Approved Drugs as Inhibitors of K
Ekins S; Gerlach J; Zorn KM; Antonio BM; Lin Z; Gerlach A
Pharm Res; 2019 Jul; 36(9):137. PubMed ID: 31332533
[TBL] [Abstract][Full Text] [Related]
3. Disordered breathing in a Pitt-Hopkins syndrome model involves Phox2b-expressing parafacial neurons and aberrant Nav1.8 expression.
Cleary CM; James S; Maher BJ; Mulkey DK
Nat Commun; 2021 Oct; 12(1):5962. PubMed ID: 34645823
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Na
Martinowich K; Das D; Sripathy SR; Mai Y; Kenney RF; Maher BJ
Mol Psychiatry; 2023 Jan; 28(1):76-82. PubMed ID: 36224259
[TBL] [Abstract][Full Text] [Related]
5. Common Pathophysiology in Multiple Mouse Models of Pitt-Hopkins Syndrome.
Thaxton C; Kloth AD; Clark EP; Moy SS; Chitwood RA; Philpot BD
J Neurosci; 2018 Jan; 38(4):918-936. PubMed ID: 29222403
[TBL] [Abstract][Full Text] [Related]
6. Impairment of different protein domains causes variable clinical presentation within Pitt-Hopkins syndrome and suggests intragenic molecular syndromology of TCF4.
Bedeschi MF; Marangi G; Calvello MR; Ricciardi S; Leone FPC; Baccarin M; Guerneri S; Orteschi D; Murdolo M; Lattante S; Frangella S; Keena B; Harr MH; Zackai E; Zollino M
Eur J Med Genet; 2017 Nov; 60(11):565-571. PubMed ID: 28807867
[TBL] [Abstract][Full Text] [Related]
7. Rescue of behavioral and electrophysiological phenotypes in a Pitt-Hopkins syndrome mouse model by genetic restoration of
Kim H; Gao EB; Draper A; Berens NC; Vihma H; Zhang X; Higashi-Howard A; Ritola KD; Simon JM; Kennedy AJ; Philpot BD
Elife; 2022 May; 11():. PubMed ID: 35535852
[TBL] [Abstract][Full Text] [Related]
8. A typical variant in TCF4 exon 18 is not associated with Pitt-Hopkins syndrome but with a familial case of mild and nonspecific neurodevelopmental disorder.
Aldeeri AA; Abu-El-Haija A
Am J Med Genet A; 2023 Apr; 191(4):1070-1076. PubMed ID: 36574749
[TBL] [Abstract][Full Text] [Related]
9. A case of Pitt-hopkins Syndrome with de novo mutation in TCF4: Clinical features and treatment for epilepsy.
Liu Y; Guo Y; Liu P; Li F; Yang C; Song J; Hu J; Xin D; Chen Z
Int J Dev Neurosci; 2018 Jun; 67():51-54. PubMed ID: 29604340
[TBL] [Abstract][Full Text] [Related]
10. The Pitt-Hopkins syndrome: report of 16 new patients and clinical diagnostic criteria.
Marangi G; Ricciardi S; Orteschi D; Lattante S; Murdolo M; Dallapiccola B; Biscione C; Lecce R; Chiurazzi P; Romano C; Greco D; Pettinato R; Sorge G; Pantaleoni C; Alfei E; Toldo I; Magnani C; Bonanni P; Martinez F; Serra G; Battaglia D; Lettori D; Vasco G; Baroncini A; Daolio C; Zollino M
Am J Med Genet A; 2011 Jul; 155A(7):1536-45. PubMed ID: 21671391
[TBL] [Abstract][Full Text] [Related]
11. Langerhans cell histiocytosis in a young patient with Pitt-Hopkins syndrome.
Macchiaiolo M; Panfili FM; Gonfiantini MV; Mastrogiorgio G; Buonuomo PS; Gaspari S; Longo D; Zollino M; Bartuli A
Am J Med Genet A; 2020 Nov; 182(11):2746-2750. PubMed ID: 32945094
[TBL] [Abstract][Full Text] [Related]
12. Two types of early epileptic encephalopathy in a Pitt-Hopkins syndrome patient with a novel TCF4 mutation.
Kirikae H; Uematsu M; Numata-Uematsu Y; Saijo N; Katata Y; Oikawa Y; Kikuchi A; Yanagi K; Kaname T; Haginoya K; Kure S
Brain Dev; 2022 Feb; 44(2):148-152. PubMed ID: 34579981
[TBL] [Abstract][Full Text] [Related]
13. Various haploinsufficiency mechanisms in Pitt-Hopkins syndrome.
Sparber P; Filatova A; Anisimova I; Markova T; Voinova V; Chuhrova A; Tabakov V; Skoblov M
Eur J Med Genet; 2020 Dec; 63(12):104088. PubMed ID: 33069932
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Cellular Function of Transcription Factor 4 in Pitt-Hopkins Syndrome.
Chen HY; Bohlen JF; Maher BJ
Dev Neurosci; 2021; 43(3-4):159-167. PubMed ID: 34134113
[TBL] [Abstract][Full Text] [Related]
15. Pitt-Hopkins syndrome-associated mutations in TCF4 lead to variable impairment of the transcription factor function ranging from hypomorphic to dominant-negative effects.
Sepp M; Pruunsild P; Timmusk T
Hum Mol Genet; 2012 Jul; 21(13):2873-88. PubMed ID: 22460224
[TBL] [Abstract][Full Text] [Related]
16. The basic helix-loop-helix transcription factor TCF4 impacts brain architecture as well as neuronal morphology and differentiation.
Schoof M; Hellwig M; Harrison L; Holdhof D; Lauffer MC; Niesen J; Virdi S; Indenbirken D; Schüller U
Eur J Neurosci; 2020 Jun; 51(11):2219-2235. PubMed ID: 31919899
[TBL] [Abstract][Full Text] [Related]
17. Proposal of a clinical score for the molecular test for Pitt-Hopkins syndrome.
Marangi G; Ricciardi S; Orteschi D; Tenconi R; Monica MD; Scarano G; Battaglia D; Lettori D; Vasco G; Zollino M
Am J Med Genet A; 2012 Jul; 158A(7):1604-11. PubMed ID: 22678594
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of TCF4 missense mutations that cause Pitt-Hopkins syndrome.
Forrest M; Chapman RM; Doyle AM; Tinsley CL; Waite A; Blake DJ
Hum Mutat; 2012 Dec; 33(12):1676-86. PubMed ID: 22777675
[TBL] [Abstract][Full Text] [Related]
19. Psychiatric Risk Gene Transcription Factor 4 Regulates Intrinsic Excitability of Prefrontal Neurons via Repression of SCN10a and KCNQ1.
Rannals MD; Hamersky GR; Page SC; Campbell MN; Briley A; Gallo RA; Phan BN; Hyde TM; Kleinman JE; Shin JH; Jaffe AE; Weinberger DR; Maher BJ
Neuron; 2016 Apr; 90(1):43-55. PubMed ID: 26971948
[TBL] [Abstract][Full Text] [Related]
20. Fatal gastrointestinal complications in Pitt-Hopkins syndrome.
Koppen IJN; Menke LA; Westra WM; Struik F; Mesman S; van Wijk MP; Huisman SA
Am J Med Genet A; 2023 Mar; 191(3):855-858. PubMed ID: 36511359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]